A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases : a non-systematic review
© 2021. International League of Associations for Rheumatology (ILAR)..
The COVID-19 pandemic has occupied the world agenda since December 2019. With no effective treatment yet, vaccination seems to be the most effective method of prevention. Recently developed vaccines have been approved for emergency use only and are currently applied to large populations. Considering both the underlying pathogenic mechanisms of autoimmune/autoinflammatory rheumatological diseases (AIIRDs) and the immunosuppressive drugs used in treatment, vaccination for COVID-19 deserves special attention in such patients. In this article, we aimed to give simple messages to the clinicians for COVID-19 vaccination in patients with AIIRDs based upon the current evidence regarding the use of other vaccines in this patient group. For this purpose, we conducted a "Pubmed search" using the following keywords: Influenza, Hepatitis B, Pneumococcal, and Shingles vaccines and the frequently used conventional and biologic disease-modifying antirheumatic drugs (DMARDs). Likewise, an additional search was performed for the COVID-19 immunization in patients with AIIRDs and considering such drugs. In summary, patients with AIIRDs should also be vaccinated against COVID-19, preferably when disease activity is under control and when there is no concurrent infection. Low-degree immunosuppression does not appear to decrease antibody responses to vaccines. Ideally, vaccinations should be done before the initiation of any biological DMARDs. Patients receiving rituximab should be vaccinated at least 4 weeks before or 6 months after treatment. Since tofacitinib may also reduce antibody responses, especially in combination with methotrexate, it may be appropriate to discontinue this drug before vaccination and to restart after 14 days of immunization. Key points • COVID-19 vaccinations should preferably be made during remission in patients with autoimmune/autoinflammatory rheumatological diseases. • Low-degree immunosuppression may not interfere with antibody response to vaccines. • Ideally, vaccinations should be made before the initiation of any biological DMARDs. • Timing of vaccination is especially important in the case of rituximab.
| Errataetall: |
CommentIn: Clin Rheumatol. 2021 Jun;40(6):2517-2518. - PMID 33928459 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Clinical rheumatology - 40(2021), 9 vom: 22. Sept., Seite 3533-3545 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Soy, Mehmet [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoimmune/autoinflammatory rheumatological diseases |
|---|
| Anmerkungen: |
Date Completed 13.08.2021 Date Revised 13.08.2021 published: Print-Electronic CommentIn: Clin Rheumatol. 2021 Jun;40(6):2517-2518. - PMID 33928459 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10067-021-05700-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323076211 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323076211 | ||
| 003 | DE-627 | ||
| 005 | 20231225183406.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10067-021-05700-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1076.xml |
| 035 | |a (DE-627)NLM323076211 | ||
| 035 | |a (NLM)33751280 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Soy, Mehmet |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases |b a non-systematic review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.08.2021 | ||
| 500 | |a Date Revised 13.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Clin Rheumatol. 2021 Jun;40(6):2517-2518. - PMID 33928459 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. International League of Associations for Rheumatology (ILAR). | ||
| 520 | |a The COVID-19 pandemic has occupied the world agenda since December 2019. With no effective treatment yet, vaccination seems to be the most effective method of prevention. Recently developed vaccines have been approved for emergency use only and are currently applied to large populations. Considering both the underlying pathogenic mechanisms of autoimmune/autoinflammatory rheumatological diseases (AIIRDs) and the immunosuppressive drugs used in treatment, vaccination for COVID-19 deserves special attention in such patients. In this article, we aimed to give simple messages to the clinicians for COVID-19 vaccination in patients with AIIRDs based upon the current evidence regarding the use of other vaccines in this patient group. For this purpose, we conducted a "Pubmed search" using the following keywords: Influenza, Hepatitis B, Pneumococcal, and Shingles vaccines and the frequently used conventional and biologic disease-modifying antirheumatic drugs (DMARDs). Likewise, an additional search was performed for the COVID-19 immunization in patients with AIIRDs and considering such drugs. In summary, patients with AIIRDs should also be vaccinated against COVID-19, preferably when disease activity is under control and when there is no concurrent infection. Low-degree immunosuppression does not appear to decrease antibody responses to vaccines. Ideally, vaccinations should be done before the initiation of any biological DMARDs. Patients receiving rituximab should be vaccinated at least 4 weeks before or 6 months after treatment. Since tofacitinib may also reduce antibody responses, especially in combination with methotrexate, it may be appropriate to discontinue this drug before vaccination and to restart after 14 days of immunization. Key points • COVID-19 vaccinations should preferably be made during remission in patients with autoimmune/autoinflammatory rheumatological diseases. • Low-degree immunosuppression may not interfere with antibody response to vaccines. • Ideally, vaccinations should be made before the initiation of any biological DMARDs. • Timing of vaccination is especially important in the case of rituximab | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Autoimmune/autoinflammatory rheumatological diseases | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a DMARDs | |
| 650 | 4 | |a Rituximab | |
| 650 | 4 | |a Vaccine | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Keser, Gökhan |e verfasserin |4 aut | |
| 700 | 1 | |a Atagunduz, Pamir |e verfasserin |4 aut | |
| 700 | 1 | |a Mutlu, Melek Yalçin |e verfasserin |4 aut | |
| 700 | 1 | |a Gunduz, Alper |e verfasserin |4 aut | |
| 700 | 1 | |a Koybaşi, Gizem |e verfasserin |4 aut | |
| 700 | 1 | |a Bes, Cemal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical rheumatology |d 1987 |g 40(2021), 9 vom: 22. Sept., Seite 3533-3545 |w (DE-627)NLM012613037 |x 1434-9949 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2021 |g number:9 |g day:22 |g month:09 |g pages:3533-3545 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10067-021-05700-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2021 |e 9 |b 22 |c 09 |h 3533-3545 | ||